This inventor holds 12 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Sanofi, Sanofi-Aventis, Sanofi-Synthelabo. Active years: 2001-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Boulogne Billancourt, FR (2001 - 2009)
- Antony, FR (2011)
- Sceaux, FR (2013)
- Paris, FR (2012 - 2017)
Company Filing History:
5 out of 1,546 
4 out of 390 
3 out of 152 
Years Active: 2001-2017
Title: **Alain Jean Braun: Innovator in VEGF Receptor Kinase Inhibitors**
Introduction
Alain Jean Braun is a distinguished inventor based in Sceaux, France, known for his significant contributions to the field of medicinal chemistry. With a remarkable portfolio of 12 patents, Braun has made substantial advancements in the development of therapeutic agents targeting key biological pathways.
Latest Patents
Among his latest innovations, Braun has developed two major patents for 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives, which serve as VEGF receptor kinase inhibitors. These inventions cover the preparation process and therapeutic applications of compounds represented by a general formula (I). This groundbreaking work highlights Braun's commitment to addressing critical health challenges through innovative solutions.
Career Highlights
Braun's professional journey includes pivotal roles in renowned pharmaceutical companies, particularly Sanofi and Sanofi-Aventis. His tenure at these companies has allowed him to leverage his expertise and collaborate on various research initiatives aimed at enhancing therapeutic efficacy in the field of oncology and beyond.
Collaborations
Throughout his career, Alain Jean Braun has collaborated with notable coworkers such as Christophe Philippo and Eric Nicolai. These partnerships have fostered a creative and productive environment, further enhancing the innovative output of Braun’s research endeavors.
Conclusion
In conclusion, Alain Jean Braun's contributions to medicinal chemistry and the development of VEGF receptor kinase inhibitors underline his status as a leading inventor in the field. With a solid foundation of patents and collaboration with esteemed professionals, Braun continues to make strides in scientific research, paving the way for future innovations in therapeutic treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile